Autres langues Biocartis Group NV

Actions

BCART

BE0974281132

Marché Fermé - Euronext Bruxelles Autres places de cotation 17:35:06 22/09/2023			Varia. 5j.	Varia. 1 janv.
0,29 ^EUR	+1,05 %		-.--%	-.--%

2023	Biocartis Group NV présente quatre résumés montrant d'excellentes données pour Idylla au congrès de l'European Society of Molecular Oncology (ESMO)	CI
2023	Biocartis Group NV annonce l'extension de sa collaboration avec APIS Assay Technologies Ltd pour commercialiser le kit de mutations ESR1 d'APIS	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)	10/01
Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)	10/01
Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)	10/01
Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion	22/11
Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting	13/11
Persbericht Biocartis Group NV: Mededeling betreffende uitwinning door gewaarborgde schuldeisers	31/10/23
Press release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors	31/10/23
Biocartis selecteert vier studie abstracts over Idylla voor ESMO-congres	20/10/23
Persbericht Biocartis Group NV: Vier abstracts, die uitstekende resultaten voor Idylla™ tonen, worden gepresenteerd op het European Society of Molecular Oncology (ESMO) congres	20/10/23
Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO)	20/10/23
Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress	20/10/23
Biocartis lanceert een borstkankerportfolio	16/10/23
Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio	16/10/23
Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio	16/10/23
Persbericht Biocartis Group NV: Biocartis steunt Borstkankermaand met lancering van een borstkankerportfolio	16/10/23
Biocartis, APIS Assay Technologies to Commercialize Estrogen Receptor-positive Mutations Kit	12/10/23
Biocartis breidt samenwerking met APIS Assay Technologies uit	12/10/23
Persbericht Biocartis Group NV: Biocartis kondigt uitbreiding aan van de samenwerking met APIS Assay Technologies en zal de APIS ESR1 Mutations Kit commercialiseren	12/10/23
Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit	12/10/23
Biocartis Group NV Announces Expansion of Its Collaboration with APIS Assay Technologies Ltd to Commercialize the APIS ESR1 Mutations Kit	12/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Biocartis Group NV

Actions

BCART

BE0974281132

Autres langues

Filtres